Labcorp Q2 revenue $3.53B, Adj EPS $4.35; raises full-year guidance

LABCORP HOLDINGS INC.

2025-Q2 EPS reported $5.36 revenue$6,872,400,000

Q2 revenue $3.53B (+9.5% YoY); diluted EPS $2.84 vs $2.43; adjusted EPS $4.35 vs $3.94.
Full-year guidance raised: revenue growth 7.5%-8.6%; adjusted EPS $16.05-$16.50; FCF $1.13-$1.28B.
Diagnostics Labs revenue $2.75B (+8.9%); Biopharma Lab Services $784.8M (+11.0%).
Quarterly dividend $0.72/share declared; $200M stock repurchased in Q2.
Announced acquisitions of select assets from Incyte Diagnostics, BioReference Health, and Community Health Systems.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.